Zafirlukast



Zafirlukast
Systematic (IUPAC) name
cyclopentyl N-[3-{[2-methoxy-4-[(2-methylphenyl)
sulfonylcarbamoyl]phenyl]methyl}-1-methyl-indol-5-yl] carbamate
Identifiers
CAS number 107753-78-6
ATC code R03DC01
PubChem 5717
DrugBank APRD00377
Chemical data
S 
mol
Pharmacokinetic data
Bioavailability Unknown
Protein binding 99%
CYP2C9-mediated)
Half life 10 hours
Excretion Biliary
Therapeutic considerations
Pregnancy cat.

B1 (Au), B (U.S.)

Legal status

POM (UK)

Routes Oral

Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), which is usually taken just once daily.

Zafirlukast blocks the action of the cysteinyl receptors, thus reducing constriction of the airways, build-up of mucus in the lungs and inflammation of the breathing passages.

Zafirlukast is marketed by AstraZeneca with the brand names Accolate, Accoleit, and Vanticon. It was the first LTRA to be marketed in the USA and is now approved in over 60 countries, including the UK, Japan, Italy, Spain, Canada, Brazil, China and Turkey.

v • d • e
Drugs for obstructive airway diseases: asthma/COPD (Ipratropium/salbutamol
 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Zafirlukast". A list of authors is available in Wikipedia.